Drugs / Pfizer COVID-19 mRNA vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06065176 Comparator | Nov 2023 → Sep 2024 | COVID-19, respiratory tract infectious disorder, upper respiratory tract disorder | Sarang K. Yoon, DO, MOH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pfizer COVID-19 mRNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06065176 ↗ |
| Known as | Pfizer-BioNTech COVID-19 vaccine | “the 2023-2024 formula of either the Novavax COVID-19 vaccine or the Pfizer-BioNTech COVID-19 vaccine” PMID 41592795 ↗ Jan 2026 |
| Modality | Messenger RNA (mRNA) | “messenger RNA (mRNA)-based COVID-19 vaccine” PMID 41592795 ↗ Jan 2026 |
| Route | Intramuscular | “in the deltoid muscle of the arm” NCT06065176 ↗ |